0
0
Read Time:19 Second
According to a proposed class action on Wednesday filed in Pensacola, Florida, federal court, the companies knew or should have known by 2018 that their marketing claims about products containing phenylephrine were false and misleading. That year was when new FDA guidance for evaluating symptoms related to nasal congestion demonstrated that earlier data about phenylephrine’s effectiveness could no longer be relied upon, the complaint said.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
